Cytokinetics Inc at Barclays Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gena Wang - Barclays - Analyst : Thank you. So maybe I will start with the commercial launch preparation. So PDUFA day, September 26 and did the FDA definitive give answer that they will be [Outcome] or no outcome?

Question: Gena Wang - Barclays - Analyst : Okay. Very helpful. And at what point do you think the FDA would discuss with you regarding the label -- potential label?

Question: Gena Wang - Barclays - Analyst : Okay. Very helpful. And maybe for Andrew, the pricing strategy. And so, maybe any thoughts there, what could be the good benchmark out there?

Question: Gena Wang - Barclays - Analyst : Okay. I think my calculation is about $100,000.

Question: Gena Wang - Barclays - Analyst : Yeah. So you think you will be north

Question: Gena Wang - Barclays - Analyst : Okay. Like price.

Question: Gena Wang - Barclays - Analyst : Of course.

Question: Gena Wang - Barclays - Analyst : That's great. So maybe like -- this is September 26. So realistically, should we see any revenue in 2025 or that will be more likely 2026 story?

Question: Gena Wang - Barclays - Analyst : Okay. And then the launch trajectory, is there any -- should we use Camzyos as a benchmark, the first, say, few quarters? Or you think you can do much better than that?

Question: Gena Wang - Barclays - Analyst : Okay. So why the first two years linear and become exponential after two years?

Question: Gena Wang - Barclays - Analyst : The last few minutes I want to ask is MAPLE since you also mentioned that this is next quarter. So maybe the expectation there and maybe share with us the initial study design thoughts? And how confident do you think that will be a positive study?

Question: Gena Wang - Barclays - Analyst : Okay. Great. Well, thank you very much. We look forward to all the updates later this year.